• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Botox for Headaches?

Article

Although the use of Botox to smooth out facial wrinkles has been approved by the Food and Drug Administration since 2002, the drug has also been used for years to treat chronic migraine headaches, even though it does not have FDA approval for this use and many skeptics doubt that it's truly effective. That may soon change.

Although the use of Botox to smooth out facial wrinkles has been approved by the Food and Drug Administration since 2002, the drug has also been used for years to treat chronic migraine headaches, even though it does not have FDA approval for this use and many skeptics doubt that it’s truly effective. That may soon change.

Allergan, which manufactures Botox, recently claimed that the results of two studies show that periodic injections of the drug can prevent headaches in patients who suffer from chronic migraines.

Allergan said that it would ask the FDA for approval to market Botox as a treatment for chronic migraines, which the company estimated affected between 1.2 million and 3.6 million Americans. Doctors can use an FDA-approved drug to treat any illness, and Allergan’s sales of Botox for migraine treatment are about $50 million a year. An FDA approval of Botox for chronic migraines, however, would allow Allergan to market Botox directly to consumers for that condition, and that could boost Botox sales for migraine treatment as high as $400 million.

Allergan did not release all the data from the studies, but critics who reviewed the research note that results in at least one of the studies were inconclusive. Officials from the America Academy of Neurology, which had issued guidelines earlier this year advising doctors that Botox injections were not an effective treatment for migraines, also noted that any speculation about whether the guidelines would change as a result of the studies would be premature.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice